Compound epidermal growth factor receptor (EGFR) mutations represent a heterogeneous
subgroup of non-small cell lung cancer (NSCLC) patients with uncommon EGFR mutations …

Background Amivantamab has been approved for the treatment of patients with advanced
non–small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 …

The Epidermal growth factor receptor (EGFR) exon (ex) 20 insertions (ins) has been
considered as an “undruggable target” for a long time, with platinum-pemetrexed …

Background Clinical guidelines advise osimertinib as preferred first line treatment for
advanced epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer …

Epidermal growth factor receptor (EGFR) exon 20 insertion mutations (ex20ins) account
for≤ 12% of all EGFR‐mutant nonsmall cell lung cancers. We analysed real‐world datasets …

The epidermal growth factor (EGF) system has allowed chemists, biologists, and clinicians to
improve our understanding of cell production and cancer therapy. The discovery of EGF led …

Epidermal growth factor receptor (EGFR) mutation is one of the key oncogenic mutations in
non-small-cell lung cancer with adenocarcinoma histology. Exon 19 deletions and exon 21 …

Introduction EGFR exon 20 insertion (ex20ins) mutations represent 5% to 10% of EGFR
mutations in NSCLC. Identifying patients with EGFR ex20ins is challenging owing to the …

Background Since their first introduction in clinical practice, immune checkpoint inhibitors
showed limited benefit in patients with NSCLC harboring EGFR mutations. With the rationale …

Introduction Real-world evidence regarding molecular epidemiology and management
patterns of patients with EGFR exon-20 mutated, advanced NSCLC outside the context of …